Erika Morrongo Bastida MD, Presenter: Nothing to Disclose

Juan Pablo Chavez Torres MD, Abstract Co-Author: Nothing to Disclose

Ailan Hitandhui Barrientos-Priego MD, Abstract Co-Author: Nothing to Disclose

Jose Rafael Garcia Ortiz MD, Abstract Co-Author: Nothing to Disclose

Maria Mayela Leon Sanchez, Abstract Co-Author: Nothing to Disclose

Irma Soldevilla-Gallardo, Abstract Co-Author: Nothing to Disclose

1.To review differences in the metabolic pathway and biodistribution of each radiopharmaceutical 2.To know the use that has been given in the literature to 18F FDG PET / CT and 11C-Acetate PET/CT in the restaging of prostate cancer 3.To identify specific conditions in each patient for the best selection of the radiopharmaceutical that provides more information in the restaging of prostate cancer 

Overview of prostate cancer Properties of 18F-FDG and 11C-Acetate Indicators of prostate cancer recurrence Review of the utility of 18F FDG PET/CT and 11C-Acetate in the restaging of prostate cancer Choice of Radiopharmaceutical Example images

http://abstract.rsna.org/uploads/2014/14015572/14015572_n6hb.pdf

Morrongo Bastida, E, Chavez Torres, J, Barrientos-Priego, A, Garcia Ortiz, J, Leon Sanchez, M, Soldevilla-Gallardo, I, Utility of 18F-FDG PET/CT and 11C-Acetate PET/CT in Restaging of Prostate Cancer: A Review of the Literature.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015572.html